Minimizing time delays in manufacturing vaccines appropriate to rapidly mutating viruses is the key step for improving vaccine effectiveness. The vaccine for the H3N2 flu type has failed for the last two years (~ 15% effective). Here we summarize the state of the predictive art and report the most current results for H3N2 flu vaccine design. Using a 2006 model of dimensional reduction of viral mutational complexity, we show that this model can reduce vaccine time delays by a year or more in some cases.
2 lengthy delay due to collection of ferret animal model data. Traditionally these two problems have most often been treated separately, while a unified treatment could result in a dramatic acceleration of vaccine design.
Early strain clustering efforts utilized both indirect measurements of viral activity, for instance, by measuring ferret responses, as well as molecular evolution at the amino acid sequential level [7, 8] . In the latter method, sequences are unambiguous, and the historical sequence data base has grown to be much larger and more timely than the still sparse and lagging-by-years ferret viral activity database [9, 10] . As a result, since 2006 both improved clustering and better dominant strain predictive results have been obtained bioinformatically for H3N2 using sequences alone. Until 2010, annual H3N2 differences were small, and the two methods were almost equally successful (8 out of 10 years for the mixed ferret-sequence method, improved to 9 out of 10 for the pure sequence method) [11, 12] .
Sequential substitutional displacements can be measured in different ways. One measure of distance between any two sequences is the number of mutations [9] . The most substitutionally active part of flu viruses is the ~ 100 amino acid head region 115-215 of the hemagglutinin protein, HA1, which contains 329 amino acids. A more refined measure of difference between strains begins by identifying the five HA1 epitopic subsets (A-E), containing the most frequently mutated amino acids in a given year, with the A and B epitope patches concentrated at the top of the head region, near the sialic acid receptor [7, 8] .
The best correlation with vaccine effectiveness to date defines distances between sequences in terms of the numbers of mutations at epitopic sites, normalized by the size of the epitope, and identifies the epitope that is dominating the difference between the current circulating strain and the lagging vaccine strain [8] . The fractional number of all mutations of this dominant epitope, p epitope , gives the best correlation with vaccine efficacy [7, 9] , with R 2 ~ 0.8 over the period 1971-2015, which is much better than one obtains from ferret data, or mixed ferret-sequence data, R 2 ~ 0.5 [8] .
An accurate and rapid way to quantify strain drift [9, 10] , and at the same time recognize formation of clusters of new strains, is to compress dimensionally the interstrain distances in the full amino acid space (for A/H3N2, 329 dimensions) to the two eigenvectors best capable of minimizing the interstrain distances over a time frame of about three years [7, 11] . Dimensional compression of sequences is 3 unbiased, and is compatible with epitopic analysis [11, 12] . Here the compression from 329 dimensions to only two dimensions can be regarded as an extreme case, which can introduce both common and distinctive features as new data are added. This point is discussed in Figs It is tempting to suppose that perhaps better predictability could be achieved by including deleterious (mostly C-E epitopes) mutations outside the A-B receptor region phylogenetically [14] . In this way, and using observed sequence data to estimate clade "fitness," some encouraging H3N2 results (inset to their Fig. 3 ) were obtained. These results stopped short of reaching a correlation with vaccine effectiveness similar to that already reported earlier [8] for A/H3N2 using all epitopes. There are several toy models of network "fitness" [15] , but they all involve only short-range connectivity, and no long-range forces.
Long-range forces can be modelled using hydropathic profiles, but as we shall soon see, they are not needed here for predicting H3N2 vaccine targets [16] [17] [18] [19] . Note the two striking nearly linear regions associated with different years in Fig. 2 . These were already present in Fig. 1 , but the lines have straightened and narrowed in Fig. 2 . This novel feature deserves more study. It is unlikely to be switching before and after 2000, which will be discussed elsewhere.
In conclusion, rapid and reliable identification of emergent strain clusters is the key to developing an effective flu vaccine. Traditional measurements of viral antigenicity or phylogenetic theories, or their combination, omit highly informative structural data used to define epitopes [22] [23] [24] , and have had only limited success (R 2 ~ 0.5). Dimensional reduction in three-year time-frame sliding sequence space, supported by identifying dominant epitopes [8, [11] [12] [13] , has proved to be more effective for H3N2 (R 2 ~ 0.8). The stakes here are high: a one-year delay in finding new H3N2 clusters has an equivalent economic value > $10 billion (a conservative estimate, considering that H3N2 morbidity is several times higher than for H1N1 [25] ). The failure of the H3N2 2014-2015 vaccine in America was responsible for 6 million additional flu cases lasting several weeks, disrupted many hospitals, and undermined public confidence in vaccinations.
Because of record late Nov. -Dec. temperature highs (~ 10°C above normal) in most of America, 2015-2016 American flu infections, reported online weekly at CDC FLUVIEW, are ambiguous at this writing.
We predict that when winter temperatures return to normal, 2015 flu epidemic severity will be less than 2014, with p epitope = 0.19, but more than 2013, with p epitope = 0.14, as predicted by the A/SwitzerlandNebraska difference with p epitope = 0.16 [13] . 
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